Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Stable isotope tracer · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Biomarker evaluation |
| Name | Type | Description |
|---|---|---|
| Stable isotope tracer (13-C(4)-BHB) | DRUG | A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes. |
Inclusion Criteria: * Subject has a Body Mass Index of 18-25 kg/m2 OR 29-40 kg/m2 * Subject has been a nonsmoker or has not used nicotine for the past 6 months Exclusion Criteria: * Subject has a history of diabetes mellitus * Subject has a history of stroke, chronic seizures, or other neurologic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
Stable isotope tracer is an investigational small molecule being studied for use in Diabetes. It is a metabolic therapeutic being developed by Merck & Company, Inc. (MRK). The compound is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials and is not yet approved for any use.
Stable isotope tracer is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this investigational small molecule for the treatment of Diabetes. Merck is responsible for the development and potential future commercialization of this metabolic therapeutic.
Stable isotope tracer is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the compound is still in the early stages of clinical testing for Diabetes.
Stable isotope tracer has one completed Phase 1 clinical trial, identified as NCT00860392. The study, titled 'A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)', enrolled 24 male participants aged 18 years and older, including healthy volunteers, and focused on Diabetes.
Stable isotope tracer is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Diabetes. The Phase 1 trial has been completed, but the compound has not yet received regulatory approval and remains in the early stages of clinical testing.